That is one reason GLP-1 and GIP medications have become part of the conversation for some patients: by helping reduce appetite, improve blood sugar control, and support meaningful weight loss, they may offer an added tool for people whose thyroid treatment alone has not solved the weight struggle
Owing to potential long-term adverse effects with chronic use of dopamine agonists, and the cost of long-term medical treatment and poor adherence in some patients, withdrawal of therapy can be considered under well-defined conditions in patients with a reasonable chance of persistent remission of hyperprolactinaemia (see Supplementary Box 6)
The FDA's 503A framework does not require the same pharmacokinetic studies as NDA approval, so hepatic-impairment data will not come from a manufacturer
They will consider factors such as the medications formulation, potential interactions with other medications, and your individual health needs to provide you with the most accurate guidance on when to take the medication for optimal effectiveness and safety
Harris SB, Khunti K, Landin-Olsson M, et al
